Ubs Group Ag Bio Atla, Inc. Transaction History

Ubs Group Ag

$452 Billion
Q3 2024

A detailed history of Ubs Group Ag transactions in Bio Atla, Inc. stock. As of the latest transaction made, Ubs Group Ag holds 10,952 shares of BCAB stock, worth $6,133. This represents 0.0% of its overall portfolio holdings.

Number of Shares

10,952

Previous 28,423 61.47%

Holding current value

$6,133

Previous $38,000 50.0%

% of portfolio

0.0%

Previous 0.0%

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$1.17 - $2.05 $20,441 - $35,815	-17,471 Reduced 61.47%	10,952 $19,000
Q2 2024 Aug 13, 2024	SELL	$1.37 - $3.92 $25,898 - $74,103	-18,904 Reduced 39.94%	28,423 $38,000
Q1 2024 May 13, 2024	SELL	$1.88 - $3.46 $872 - $1,605	-464 Reduced 0.97%	47,327 $162,000
Q4 2023 Feb 09, 2024	BUY	$1.27 - $3.18 $31,969 - $80,050	25,173 Added 111.3%	47,791 $117,000
Q3 2023 Nov 09, 2023	SELL	$1.7 - $3.07 $3,360 - $6,069	-1,977 Reduced 8.04%	22,618 $38,000
Q2 2023 Aug 11, 2023	BUY	$2.83 - $3.87 $69,603 - $95,182	24,595 New	24,595 $73,000
Q4 2022 Feb 08, 2023	SELL	$6.29 - $11.01 $15,806 - $27,668	-2,513 Reduced 45.0%	3,071 $25,000
Q3 2022 Nov 10, 2022	BUY	$2.94 - $11.87 $16,416 - $66,282	5,584 New	5,584 $43,000
Q1 2022 May 16, 2022	SELL	$4.38 - $18.78 $310,953 - $1.33 Million	-70,994 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$19.0 - $30.95 $597,379 - $973,098	31,441 Added 79.49%	70,994 $1.39 Million
Q3 2021 Nov 15, 2021	BUY	$29.44 - $43.74 $1.1 Million - $1.63 Million	37,289 Added 1647.04%	39,553 $1.16 Million
Q2 2021 Aug 13, 2021	SELL	$38.07 - $56.17 $10,050 - $14,828	-264 Reduced 10.44%	2,264 $96,000
Q1 2021 May 12, 2021	BUY	$32.41 - $70.91 $65,533 - $143,380	2,022 Added 399.6%	2,528 $129,000
Q4 2020 Feb 11, 2021	BUY	$31.02 - $35.16 $15,696 - $17,790	506 New	506 $17,000

Others Institutions Holding BCAB

# of Institutions

Shares Held

17.5M

Call Options Held

500

Put Options Held

33.5K

View Full List

About BioAtla, Inc.

Ticker BCAB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 36,304,100
Market Cap $20.3M
Description
BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ...

More about BCAB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account